Total raised
—
Last: Seed 2018-12
Stage
Seed
Founded
2017
Headcount
2
HQ
Kefar Sava
Sector
Health Tech & Life Sciences
About
Feramda Biopharmaceutical develops safe tellurium-based oral drugs that are designed to reduce the number of intravitreal anti-vascular endothelial growth factor injections needed in the treatment of wet age-related macular degeneration, a disease that can cause blindness. Tellurium-based molecules inhibit angiogenesis through a unique mechanism of action that increases angiogenesis inhibitors in the eye and inhibits inflammation.
Funding history · 1 round · — total
2018-12
Seed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
oral-drugsseniorsbiopharmaceuticalpharmaceuticalsophthalmologyeye-diseasesdrug-discovery